Askel Healthcare to raise 5 million euros for clinical research of its COPLA® -implant to treat knee pain caused by cartilage damage
Askel Healthcare, the Finnish medical technology company offering a new method for the treatment of knee cartilage damage, has started a fundraising campaign to raise up to 5 million euros to finance clinical trials of its COPLA[®] implant. The public phase of the ongoing fundraising campaign started today and closes on 18 June 2023. An investor meeting will take place on 24 May 2023 at 16:00 EEST at VALO Hotel & Work and online. Askel Healthcare’s COPLA[®] implant is a new biodegradable implant for the surgical treatment of cartilage damage in the knee. Askel Healthcare is targeting the